Product
Brentuximab
2 clinical trials
2 indications
Indication
Peripheral T-cell LymphomaIndication
Hodgkin's lymphomaClinical trial
A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 ExpressionStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812)Status: Terminated, Estimated PCD: 2021-02-22